online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 4 of 7
Up
ECPB 2021, 93(3): 33–38
https://doi.org/10.25040/ecpb2021.03-04.033
Research articles

The effect of liraglutide on eating disorders in patients with type 2 diabetes

A.M. URBANOVYCH, F.V. LANIUSH
Abstract

Eating Disorders (ED) – Binge eating disorder (BED) and Night eating syndrome (NES)-are hyperphagic ED which can cause obesity and diabetes type 2 (DT2) decompensation by increasing glycated hemoglobin (HbA1c), LDL, and triglycerides, which belong to the major risk factors of cardiovascular events. The main hormonal regulators of eating behavior are leptin and ghrelin. Leptin levels are increased in DT2 patients with obesity, binge eaters and people with NES. In contrast to leptin, ghrelin levels are decreased in those patients. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are used for DT2 and obesity management. Since GLP-1 RA suppress eating behavior, reduce body weight, and optimize glucose control, they are potential candidates for the treatment of BE and NES. The aim of our study was to assess the effect of liraglutide on BE and NES in patients with DT2 and obesity. We examined 86 patients: 13 of them were screened positive for BE and 9 for NES. We divided them into 2 groups: the 1st group was taking only metformin for DT2 management; the 2nd one – metformin and liraglutide. After 3 months the patients were again examined: the 2nd group demonstrated statistically significant weight reduction, leptin levels decreased, ghrelin levels increased. Patient with BES showed lower scores of Binge eating scale and increased number of binge episodes.We suggest that use of GLP-1 RA for the management of BES and NES can be efficacious in DT2 and obese patients.

Keywords: diabetes, obesity, eating disorders, GLP-1 RA

Full text: PDF (Ukr) 272K

References
  1. 1. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. American Journal of Physiology-Endocrinology and Metabolism. 2020;318.5: E736-E741.
  2. 2. Javaras KN, Pope HG, Lalonde JK, Roberts JL, Nillni YI, Laird NM, et al. Co-occurrence of binge eating disorder with psychiatric and medical disorders. J Clin Psychiatry. 2008;69(2):266-73.
  3. 3. Mechanick J., Zhao Sh.,Garvey W. Leptin, an adipokine with central importance in the global obesity problem. Global heart, 2018, 13.2: 113-127.
  4. 4. Урбанович АМ. Гормони жирової тканини та їх клінічне значення. Ендокринологія. 2013; 18.1:69-72.
  5. 5. Kojima M, Hosoda H, Date Y, Nakazato M et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999; 378 402:656-60.
  6. 6. Drucker D. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 2021, 101351.
  7. 7. American Diabetes Association. (2021). Disclosures: Standards of Medical Care in Diabetes-2021.
  8. 8. Schutz D. et al. European practical and patient-centred guidelines for adult obesity management in primary care. Obesity facts, 2019, 12.1: 40-66.
  9. 9. Laniush FV, Urbanovych AM. Опитувальник для визначення синдрому нічного переїдання (NEQ)-валідація та адаптація для української популяції. Ендокринологія, 2021, 26.3: 311-318.
  10. 10. Ланюш Ф.В., Урбанович А.М. Фізіологічні особливості лептину у хворих із цукровим діабетом 2-го типу та порушеннями харчової поведінки. Experimental and clinical physiology and biochemistry ECPB. 2020; 3/4(91): 20-25.
  11. 11. American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and Statistical Manual of Mental Disorders : DSM-5. American Psychiatric Association; 2013.
  12. 12. De Zwaan M, Marschollek M, Allison KC. European Eating Disorders Review. 2015.
  13. 13. Hilbert A, Pike KM, Goldschmidt AB, et al. Psychiatry Research. 2014; 220:500-506.
  14. 14. de Zwaan M, Müller A, Allison KC, Brähler E, Hilbert A. Prevalence and correlates of night eating in the German general population. PLoS One. 2014 May 14;9(5):e97667.
  15. 15. Meneghini LF, Spadola J, Florez H. Prevalence and associations of binge eating disorder in a multiethnic population with type 2 diabetes. Diabetes Care. 2006 Dec;29(12):2760.
  16. 16. Adami GF, Campostano A, Cella F, Scopinaro N. Serum leptin concentration in obese patients with binge eating disorder. International Journal of Obesity. 2002. Vol. 26(8). P. 1125-8.
  17. 17. Monteleone P, Di Lieto A, Tortorella A, Longobardi N, et. al. Opposite modifications in circulating leptin and soluble leptin receptor across the eating disorder spectrum. Psychiatry research. 2000. Vol. 94(2). P. 121-9.
  18. 18. Imbeault P, Doucet E, Mauriege P, et al. Difference in leptin response to a high-fat meal between lean and obese men. Clinical Science. 2001;101:359-365.
  19. 19. Panagopoulos VN, Ralevski E. The role of ghrelin in addiction: a review. Psychopharmacology. 2014;231:2725-40.
  20. 20. Skibicka KP, Shirazi RH, Rabasa-Papio C, Alvarez-Crespo M, et al. Divergent circuitry underlying food reward and intake effects of ghrelin: dopaminergic VTA-accumbens projection mediates ghrelin's effect on food reward but not food intake. Neuropharmacology. 2013; 73:274-83.
  21. 21. Waxman SE. A systematic review of impulsivity in eating disorders. European Eating Disorders Review. 2009;17:408-25.
  22. 22. Shiiya T, Nakazato M, Mizuta M, Date Y, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. Journal of Clinical Endocrinology and Metabolism. 2002; 87:240-4.
  23. 23. Iceta S, Julien B, Seyssel K, Lambert-Porcheron S, Segrestin B, Blond E, et al. Ghrelin concentration as an indicator of eating-disorder risk in obese women. Diabetes and Metabolism. 2018; 45(2), 160-166.
  24. 24. Dominica Hernandez, Nandini Mehta, and Allan Geliebter. Meal‐related acyl and des‐acyl ghrelin and other appetite‐related hormones in people with obesity and binge eating. Obesity. 2019; 27:629-635.
  25. 25. Chevinsky JD, Wadden TA, & Chao AM. Binge Eating Disorder in Patients with Type 2 Diabetes: Diagnostic and Management Challenges. Diabetes, metabolic syndrome and obesity : targets and therapy. 2020; 13:1117-1131.
  26. 26. Citrome, L. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International journal of clinical practice. 2015; 69(4):410-421.
  27. 27. Kucukgoncu S, Midura M, & Tek C. Optimal management of night eating syndrome: challenges and solutions. Neuropsychiatric disease and treatment. 2015
  28. 28. Da Porto A, Casarsa V, Colussi G, Catena C, Cavarape A, & Sechi L. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020; 14(4): 289-292.
  29. 29. Robert SA, Rohana AG, Shah SA, Chinna K, Mohamud WNW, & Kamaruddin NA. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide-A pilot study. Obesity research & clinical practice. 2015; 9(3):301-304.


Програмування - Roman.im